Compare Mattel Inc (MAT) vs Neurocrine Biosciences Inc (NBIX) Price & Performance

Mattel (MAT) trades at $14.165, down 0.94% today, with a bullish technical signal supported by moving averages. The stock shows attractive valuation with a P/E of 9.17 and P/S of 0.84, while recent earnings have been mixed with Q1 2026 beating expectations but Q3 and Q4 2025 missing. Revenue remains stable around $5.4B, and the company maintains strong brand collaborations, as seen with recent Hot Wheels and Barbie partnerships.

Outlook is cautiously optimistic given undervaluation and analyst consensus, but risks include stagnant sales, debt levels, and recent negative cash flow trends. The consensus price target is $14.60, suggesting limited upside from current levels, with investor sentiment divided between value opportunity and near-term headwinds.

Neurocrine Biosciences (NBIX) trades at $173.00, up 1.24% with strong bullish momentum. Recent earnings beats, including Q1 2026 EPS of $1.94 versus $1.22 expected, underscore robust growth. The stock shows bullish technical signals with support at $170 and resistance at $173. Revenue growth accelerated to $2.86 billion in 2025, with net income margin improving to 21.55% in 2026 projections. Positive news highlights pipeline advancements and the Soleno acquisition.

Outlook remains positive with a consensus price target of $196.08, implying 13% upside. Key opportunities include sustained earnings growth and pipeline expansion, while risks involve clinical trial outcomes and competitive pressures. Institutional sentiment is strongly bullish with 86% buy ratings.